S&P 500   4,293.93
DOW   33,833.61
QQQ   353.15
High Dividend REITs: Are They an Ideal Way to Diversify?
This Company Is Solving A Multi-Billion Dollar Problem! (Ad)
Stock market today: Asian shares mostly rise, lifted by bull market on Wall Street
2 Dow Stocks Trading Less Than 10x Earnings are Blue Chip Values
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Boost for homebuyers: Average long-term US mortgage rate eases from 7-month high to 6.71% this week
6 Best Online and Direct Marketing Retail Stocks to Invest in
This Company Is Solving A Multi-Billion Dollar Problem! (Ad)
Homebuilding Stocks Defying Cooling Housing Market: Time to Sell?
US applications for jobless benefits highest since October 2021
S&P 500   4,293.93
DOW   33,833.61
QQQ   353.15
High Dividend REITs: Are They an Ideal Way to Diversify?
This Company Is Solving A Multi-Billion Dollar Problem! (Ad)
Stock market today: Asian shares mostly rise, lifted by bull market on Wall Street
2 Dow Stocks Trading Less Than 10x Earnings are Blue Chip Values
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Boost for homebuyers: Average long-term US mortgage rate eases from 7-month high to 6.71% this week
6 Best Online and Direct Marketing Retail Stocks to Invest in
This Company Is Solving A Multi-Billion Dollar Problem! (Ad)
Homebuilding Stocks Defying Cooling Housing Market: Time to Sell?
US applications for jobless benefits highest since October 2021
S&P 500   4,293.93
DOW   33,833.61
QQQ   353.15
High Dividend REITs: Are They an Ideal Way to Diversify?
This Company Is Solving A Multi-Billion Dollar Problem! (Ad)
Stock market today: Asian shares mostly rise, lifted by bull market on Wall Street
2 Dow Stocks Trading Less Than 10x Earnings are Blue Chip Values
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Boost for homebuyers: Average long-term US mortgage rate eases from 7-month high to 6.71% this week
6 Best Online and Direct Marketing Retail Stocks to Invest in
This Company Is Solving A Multi-Billion Dollar Problem! (Ad)
Homebuilding Stocks Defying Cooling Housing Market: Time to Sell?
US applications for jobless benefits highest since October 2021
S&P 500   4,293.93
DOW   33,833.61
QQQ   353.15
High Dividend REITs: Are They an Ideal Way to Diversify?
This Company Is Solving A Multi-Billion Dollar Problem! (Ad)
Stock market today: Asian shares mostly rise, lifted by bull market on Wall Street
2 Dow Stocks Trading Less Than 10x Earnings are Blue Chip Values
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Boost for homebuyers: Average long-term US mortgage rate eases from 7-month high to 6.71% this week
6 Best Online and Direct Marketing Retail Stocks to Invest in
This Company Is Solving A Multi-Billion Dollar Problem! (Ad)
Homebuilding Stocks Defying Cooling Housing Market: Time to Sell?
US applications for jobless benefits highest since October 2021
NASDAQ:RPHM

Reneo Pharmaceuticals (RPHM) Stock Forecast, Price & News

$8.84
-0.12 (-1.34%)
(As of 06/8/2023 ET)
Compare
Today's Range
$8.61
$9.45
50-Day Range
$5.44
$10.50
52-Week Range
$1.79
$11.30
Volume
71,600 shs
Average Volume
84,830 shs
Market Capitalization
$297.55 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.00

Reneo Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
216.7% Upside
$28.00 Price Target
Short Interest
Healthy
2.34% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$1 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.31) to ($2.25) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.16 out of 5 stars

Medical Sector

168th out of 986 stocks

Pharmaceutical Preparations Industry

74th out of 473 stocks


RPHM stock logo

About Reneo Pharmaceuticals (NASDAQ:RPHM) Stock

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. Its lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. The company was incorporated in 2014 and is headquartered in Irvine, California.

Receive RPHM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Reneo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RPHM Stock News Headlines

How A.I. Could Make Most 21st Century Diseases EXTINCT
On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...
RPHM Reneo Pharmaceuticals, Inc.
This Company Is Solving A Multi-Billion Dollar Problem!
This Little Known NASDAQ Stock is Solving a Multi-Billion Dollar Problem!
Reneo Pharmaceuticals (NASDAQ:RPHM) Announces Earnings Results
See More Headlines

RPHM Price History

RPHM Company Calendar

Last Earnings
3/27/2023
Today
6/08/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RPHM
Fax
N/A
Employees
24
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$28.00
High Stock Price Forecast
$31.00
Low Stock Price Forecast
$25.00
Forecasted Upside/Downside
+216.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-51,960,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.08 per share

Miscellaneous

Free Float
27,631,000
Market Cap
$297.55 million
Optionable
Not Optionable
Beta
1.24

Key Executives

  • Mr. Michael G. Grey (Age 69)
    Founder & Exec. Chairman
  • Mr. Gregory J. FlesherMr. Gregory J. Flesher (Age 52)
    Pres, CEO & Director
    Comp: $743.05k
  • Mr. Michael P. CruseMr. Michael P. Cruse (Age 50)
    Chief Operating Officer
    Comp: $423.3k
  • Mr. Vineet R. JindalMr. Vineet R. Jindal (Age 44)
    Consultant
    Comp: $568.27k
  • Ms. Jennifer P. Lam
    Principal Financial & Accounting Officer
  • Ms. Wendy S. Johnson M.B.A. (Age 70)
    Consultant
  • Dr. Alejandro Dorenbaum M.D. (Age 61)
    Chief Medical Officer
  • Ms. Lynn Purkins Ph.D.
    Sr. VP of Clinical Operations
  • Ms. Ashley F. Hall J.D. (Age 50)
    Chief Devel. Officer













RPHM Stock - Frequently Asked Questions

Should I buy or sell Reneo Pharmaceuticals stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Reneo Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RPHM shares.
View RPHM analyst ratings
or view top-rated stocks.

What is Reneo Pharmaceuticals' stock price forecast for 2023?

2 brokers have issued twelve-month price targets for Reneo Pharmaceuticals' shares. Their RPHM share price forecasts range from $25.00 to $31.00. On average, they expect the company's share price to reach $28.00 in the next twelve months. This suggests a possible upside of 216.7% from the stock's current price.
View analysts price targets for RPHM
or view top-rated stocks among Wall Street analysts.

How have RPHM shares performed in 2023?

Reneo Pharmaceuticals' stock was trading at $2.33 at the beginning of the year. Since then, RPHM shares have increased by 279.4% and is now trading at $8.84.
View the best growth stocks for 2023 here
.

Are investors shorting Reneo Pharmaceuticals?

Reneo Pharmaceuticals saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 255,600 shares, an increase of 121.1% from the April 30th total of 115,600 shares. Based on an average trading volume of 107,500 shares, the short-interest ratio is currently 2.4 days. Currently, 2.3% of the shares of the stock are sold short.
View Reneo Pharmaceuticals' Short Interest
.

When is Reneo Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our RPHM earnings forecast
.

How were Reneo Pharmaceuticals' earnings last quarter?

Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) announced its earnings results on Monday, March, 27th. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.03.

When did Reneo Pharmaceuticals IPO?

(RPHM) raised $101 million in an initial public offering on Friday, April 9th 2021. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, SVB Leerink and Piper Sandler served as the underwriters for the IPO.

What is Reneo Pharmaceuticals' stock symbol?

Reneo Pharmaceuticals trades on the NASDAQ under the ticker symbol "RPHM."

Who are Reneo Pharmaceuticals' major shareholders?

Reneo Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Carlyle Group Inc. (8.26%), ExodusPoint Capital Management LP (0.98%), Great Point Partners LLC (0.48%), Geode Capital Management LLC (0.38%), Federated Hermes Inc. (0.31%) and MAI Capital Management (0.21%). Insiders that own company stock include Bali Muralidhar, Gregory J Flesher, Holdings A/S Novo, Michael Cruse, Niall O'donnell, Venture Fund Iii L Rivervest and Vineet R Jindal.
View institutional ownership trends
.

How do I buy shares of Reneo Pharmaceuticals?

Shares of RPHM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Reneo Pharmaceuticals' stock price today?

One share of RPHM stock can currently be purchased for approximately $8.84.

How much money does Reneo Pharmaceuticals make?

Reneo Pharmaceuticals (NASDAQ:RPHM) has a market capitalization of $297.55 million. The company earns $-51,960,000.00 in net income (profit) each year or ($2.19) on an earnings per share basis.

How can I contact Reneo Pharmaceuticals?

The official website for the company is reneopharma.com. The company can be reached via phone at 858-283-0280 or via email at investors@reneopharma.com.

This page (NASDAQ:RPHM) was last updated on 6/9/2023 by MarketBeat.com Staff

My Account -